Vertex Pharmaceuticals Incorporated
Research & Development
11010 Torreyana Road
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.
Vertex Pharmaceuticals is an Equal Opportunity Employer.
Key Contacts Media: firstname.lastname@example.org Investors: email@example.com Patient Inquiries: firstname.lastname@example.org
184 articles about Vertex Pharmaceuticals Incorporated
Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members
Vertex Pharmaceuticals Incorporated announced the recipients of scholarships as part of its second All in for CF Scholarship program.
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the first quarter ended March 31, 2018.
Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
Vertex Pharmaceuticals Incorporated announced that it is initiating two Phase 3 studies of VX-445.
Q-State Biosciences, Inc. today announced that the company has entered into a strategic collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to discover drugs using Q-State’s novel Optopatch™ platform.
GlobalDataWith the Threat of Competition Looming, Vertex Pharmaceuticals (MA) Boasts of Promising New HCV Therapy
Vertex Pharmaceuticals (CA): Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis
Vertex Pharmaceuticals (CA) Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need
Vertex Pharmaceuticals (CA) Announces the Date of its Full Year 2010 Financial Results Conference Call and Webcast
Vertex Pharmaceuticals (CA) Announces Key Business Objectives To Support Planned Launch of Telaprevir in Hepatitis C and Continued Progress in Other Serious Diseases
Vertex Pharmaceuticals (CA) Announces Webcast of its Presentation at the 29th Annual J.P. Morgan Healthcare Conference
"Warehoused" Hepatitis C Patients May Boost Merck & Co., Inc., Johnson & Johnson, Vertex Pharmaceuticals (CA)
Vertex Pharmaceuticals (CA) Announces the Date of its First Quarter 2010 Financial Results Conference Call and Webcast
Vertex Pharmaceuticals (CA) Reviews 2010 Business Priorities to Support Goal of Becoming Fully-Capable Biopharmaceutical Company
Bend Research and Vertex Pharmaceuticals (CA) Enter New Scientific Collaboration Bend to Provide Novel Formulation Development and Manufacturing Services for Specific Vertex-led Projects and Clinical Trials